Do patients consider postoperative maintenance therapy for Crohn's disease worthwhile?
BACKGROUND
Treatment decision making for postoperative Crohn's disease is complex because of the increasing number of maintenance therapies available with competing risk-benefit profiles. The main objective of this study was to determine the distribution of patients' preferences for selected postoperative maintenance therapies.


METHODS
The study was a cross-sectional survey in which patients with Crohn's disease completed a standardized interview. Each participant completed 5 tasks that compared: (1) no medication and 5-ASA, (2) fish oil and 5-ASA, (3) metronidazole and 5-ASA, (4) budesonide and 5-ASA, and (5) azathioprine and 5-ASA. For each task, the minimum change in treatment effect size between the 2 treatments that the participant considered worthwhile was determined.


RESULTS
The distribution of the participants' preference scores varied widely for each task. When fish oil, metronidazole, budesonide, and azathioprine were considered equally effective to 5-ASA, 92.9%, 28.8%, 38.4%, and 19% of the participants, respectively, preferred these medications relative to 5-ASA. These percentages increased to 98.4%, 54.8%, 61.9%, and 50.8%, respectively, when fish oil, metronidazole, budesonide, and azathioprine were considered to offer a 5% absolute risk reduction relative to 5-ASA. Regression analysis did not identify any clinical or demographic variables predictive of the participants' treatment preferences.


CONCLUSIONS
The participants' preferences for postoperative maintenance therapies were widely distributed, and no clinical or demographic factors predicted these preferences. This emphasizes the need for effective communication between physician and patient in order to select the treatment options most consistent with a patient's informed preferences.
Kennedy
Erin D
ED
Department of Surgery, Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada.
To
Theresa
T
Steinhart
A Hillary
AH
Detsky
Allan
A
Llewellyn-Thomas
Hilary A
HA
McLeod
Robin S
RS
D000328:Adult; D000368:Aged; D001379:Azathioprine / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D019819:Budesonide / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D002170:Canada; D003424:Crohn Disease / Q000188:drug therapy* / Q000601:surgery; D003430:Cross-Sectional Studies; D003661:Decision Support Techniques; D005252:Fees, Pharmaceutical; D005260:Female; D005395:Fish Oils / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D017144:Focus Groups; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D019804:Mesalamine / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D008795:Metronidazole / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D008875:Middle Aged; D017060:Patient Satisfaction; D011182:Postoperative Care; D012044:Regression Analysis; D015203:Reproducibility of Results; D055502:Secondary Prevention
D005395:Fish Oils; D005765:Gastrointestinal Agents; D008795:Metronidazole; D019804:Mesalamine; D019819:Budesonide; D001379:Azathioprine